#USA #Robbins Geller #San Diego #Class Action #Ultragenyx

Investor Alert: Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing treatments for rare genetic diseases, has found itself at the center of a class action lawsuit initiated by Robbins Geller Rudman & Dowd LLP. This legal action is aimed at investors who acquired Ultragenyx shares between August 3, 2023, and December 26, 2025. The firm is seeking to represent those who incurred significant financial losses during this period.

Class Action Details

The lawsuit, filed under the title Bailey v. Ultragenyx Pharmaceutical Inc., alleges violations of the Securities Exchange Act of 1934 by the company and its executives. Investors who suffered substantial losses during the class period now have the opportunity to step forward as lead plaintiffs in the lawsuit. The aim is to represent the interests of fellow shareholders who may also have been adversely affected.

The core allegations center around Ultragenyx's optimistic assertions about its clinical trials. Specifically, the lawsuit claims the company misled investors by presenting information about its Phase III Orbit study on setrusumab, a treatment for Osteogenesis Imperfecta (OI). According to the complaint, Ultragenyx executives created a favorable impression of their data while downplaying the risks of inconclusive results. The complaint explains that the touted reduction in the annualized fracture rate (AFR) may have been overstated, as it failed to fully account for the lack of a placebo control group in earlier studies.

Background of the Case

The key events leading to the current situation include a disclosure on July 9, 2025, when Ultragenyx announced that its Phase III Orbit study did not meet the statistical significance needed for its interim analysis. Following this news, the stock price plummeted by more than 25%. Furthermore, on December 29, 2025, the company confirmed that its studies had not achieved the expected clinical outcome, leading to an additional drop in stock value, this time by over 42%.

The lawsuit highlights how Ultragenyx's statements during the class period were misleading, ultimately impacting the financial status of its investors. This raises serious concerns over the company’s transparency and accountability.

Process to Become a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who holds shares during the defined class period can petition to become the lead plaintiff in the suit. To qualify, the individual must demonstrate the greatest financial loss and show they can adequately represent the interests of the other affected shareholders.

The lead plaintiff will guide the case and can choose a law firm to handle the litigation, although recovering potential damages is not contingent on serving as the lead plaintiff. Those affected are encouraged to evaluate their options and consider becoming involved in the lawsuit.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is recognized as a leading law firm specializing in securities class action recoveries. It secured the top spot in the ISS Securities Class Action Services Top 50 Report, recovering over $916 million for investors in 2025 alone. The firm is known for its effectiveness, having reclaimed $8.4 billion for investors over the past five years. With a vast network of attorneys, Robbins Geller has a proven track record in handling major securities lawsuits and representing shareholder interests against fraudulent practices.

Investors looking to partake in this lawsuit can provide their information directly through Robbins Geller's website or can reach out via phone or email. The time for action is critical, as the window to join the lawsuit may be limited.

In conclusion, the unfolding developments surrounding Ultragenyx Pharmaceutical Inc. serve as a stark reminder for investors to remain vigilant and informed. Those impacted by the company's recent announcements have a chance to reclaim their losses by participating in this class action lawsuit.